Acute-on-Chronic Liver Failure (ACLF) Market By Disease Type (Type-A ACLF, Type-B ACLF, Type-C ACLF); By Therapy / Treatment Type (Liver Transplantation, Medications / Pharmacotherapy, Supportive Care, Other Treatments); By End User (Hospitals, Specialty Clinics and Research Institutes, Ambulatory Surgical Centers and Other Outpatient Facilities); By Geography (Asia-Pacific, North America, Europe, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Acute-on-Chronic Liver Failure Market: Transplant Demand Meets a New Drug Pipeline – (Updated On: 1st-Oct-2026)

The Global Acute-on-Chronic Liver Failure (ACLF) Market was valued at USD 3.35 billion in 2025 and is projected to reach USD 5.59 billion by 2032, expanding at a CAGR of 7.58% during 2026–2032.

 

The addressable clinical burden remains substantial, with an estimated 3.7 million potential ACLF patients globally. A meta-analysis of 30 cohort studies reported ACLF in approximately 35% of patients hospitalized with decompensated cirrhosis. In the United States, 19,082 ACLF patients were identified among 72,316 hospitalized decompensated cirrhosis patients, representing 26.4% of the cohort. In Europe, ACLF prevalence among hospitalized patients with decompensated cirrhosis has been reported at approximately 39%, while healthcare data from Germany, France, Italy, and Denmark recorded 1.60 million cirrhosis admissions over four years, including 329,093 admissions involving at least one extrahepatic organ failure.

 

Pipeline activity is focused on reducing progression to severe multi-organ failure. GENFIT reported Phase 1 data for G1090N in January 2026, while Yaqrit continued development of YAQ005 through its Phase 2 A-TANGO program in 2026. Grifols Therapeutics also remains commercially relevant through albumin-based products used in the management of advanced liver disease.

 

Market growth is therefore closely linked to the large hospitalized cirrhosis population, high rates of organ failure, and the limited availability of disease-modifying treatment options, creating demand for therapies that can stabilize patients and reduce progression to severe ACLF.

 

Key Takeaways: Transplant Economics Anchor Revenue While Pharmacotherapy and Asia-Pacific Accelerate Growth

By Disease Type

• Type-C ACLF accounts for an estimated 52% share, equivalent to approximately USD 1.742 billion in 2025 revenue, and is projected to expand at a CAGR of 7.20% during 2026–2032. Its dominance reflects the large pool of patients with established cirrhosis who develop acute decompensation following infections, alcohol-related injury, bleeding, or other secondary insults.

• Type-B ACLF represents approximately 31% of the market, generating around USD 1.038 billion in 2025 revenue, and is expected to grow at a CAGR of 7.90% during 2026–2032. Chronic viral hepatitis and compensated cirrhosis remain important contributors, particularly across Asian markets with substantial HBV-related liver disease.

• Type-A ACLF holds approximately 17% share, corresponding to USD 0.570 billion in 2025 revenue, and is projected to record the fastest disease-type CAGR of approximately 8.20% during 2026–2032 as earlier recognition of severe acute deterioration among patients with non-cirrhotic chronic liver disease improves.

 

By Therapy / Treatment Type

• Liver Transplantation holds the largest estimated 38% share, representing approximately USD 1.273 billion in 2025 revenue, and is projected to expand at a CAGR of 6.70% during 2026–2032. The segment includes deceased-donor liver transplantation and living-donor liver transplantation and remains the principal definitive treatment for eligible patients with severe ACLF.

• Medications / Pharmacotherapy account for approximately 30% share, equivalent to USD 1.005 billion in 2025 revenue, and are projected to record the fastest CAGR of approximately 9.17% during 2026–2032. The segment includes albumin therapy, antibiotics, anti-inflammatory and immunomodulatory agents, gut-targeted therapies, and emerging investigational ACLF drugs.

• Supportive Care represents an estimated 25% share, generating approximately USD 0.838 billion in 2025 revenue, and is projected to expand at a CAGR of 7.40% during 2026–2032. Major subsegments include renal replacement therapy, mechanical ventilation, vasopressor support, artificial liver-support systems such as MARS, and intensive organ-support management.

• Other Treatments account for approximately 7% share, equivalent to USD 0.234 billion in 2025 revenue, and are expected to grow at a CAGR of 5.80% during 2026–2032. These include nutritional intervention, management of portal-hypertension complications, bleeding control, and other adjunctive treatments.

 

By End User

• Hospitals dominate with approximately 78% share, representing USD 2.613 billion in 2025 revenue, and are projected to expand at a CAGR of approximately 7.41% during 2026–2032. ICU utilization, management of multiorgan failure, infection treatment, dialysis, ventilation, and transplant assessment concentrate ACLF expenditure within hospital settings.

• Specialty Clinics and Research Institutes account for approximately 14% share, equivalent to USD 0.469 billion in 2025 revenue, and are projected to record the fastest end-user CAGR of 9.40% during 2026–2032, supported by growing clinical-trial activity and specialist hepatology programs.

• Ambulatory Surgical Centers and Other Outpatient Facilities represent approximately 8% share, corresponding to USD 0.268 billion in 2025 revenue, and are projected to grow at a CAGR of 5.90% during 2026–2032. Their role remains concentrated primarily in diagnostic procedures, post-discharge monitoring, and selected follow-up services rather than acute ACLF management.

 

By Geography

• Asia-Pacific holds the largest estimated 43% share, representing approximately USD 1.441 billion in 2025 revenue, and is projected to record the fastest regional CAGR of approximately 8.53% during 2026–2032. China and India contribute substantially to the addressable patient pool because of their large populations affected by chronic viral hepatitis, cirrhosis, and other chronic liver diseases.

• North America accounts for approximately 26% share, equivalent to USD 0.871 billion in 2025 revenue, and is projected to expand at a CAGR of 6.50% during 2026–2032. Advanced ICU infrastructure, liver-transplant programs, high treatment expenditure, and clinical development support regional revenue.

• Europe represents approximately 22% share, corresponding to USD 0.737 billion in 2025 revenue, and is expected to grow at a CAGR of 6.90% during 2026–2032. Established transplant networks and specialist hepatology programs across Germany, France, the UK, Spain, and Italy support treatment utilization.

• Latin America contributes approximately 5% share, equivalent to USD 0.168 billion in 2025 revenue, and is projected to expand at a CAGR of 7.50% during 2026–2032, supported by increasing diagnosis of alcohol-related and metabolic liver disease.

• Middle East & Africa account for approximately 4% share, representing around USD 0.134 billion in 2025 revenue, and are projected to grow at a CAGR of 7.90% during 2026–2032, with expansion linked to improving hepatology services and the continuing burden of viral and metabolic liver diseases.

 

High-Value Treatment Pools and Emerging Growth Engines Reshaping the ACLF Market

By Disease Type

Leading Subsegment: Type-C ACLF

Type-C ACLF leads the Acute-on-Chronic Liver Failure Market by disease type, accounting for an estimated 52% share and approximately USD 1.742 billion in 2025 revenue. The segment is projected to grow at a CAGR of 7.20% during 2026–2032, reaching nearly USD 2.83 billion by 2032. Type-C ACLF occurs in patients with previously decompensated cirrhosis and is associated with poor physiological reserve, frequent multi-organ failure, high mortality, and substantial demand for intensive care and liver transplantation.

Fastest-Growing Subsegment: Type-A ACLF

Type-A ACLF accounts for an estimated 17% of the Acute-on-Chronic Liver Failure Market, generating approximately USD 0.570 billion in 2025 revenue, and is projected to expand at the fastest disease-type CAGR of 8.20% during 2026–2032. Type-A ACLF involves acute hepatic deterioration in patients with chronic liver disease but without established cirrhosis. Its market growth is supported by hepatitis B flares, metabolic liver disease, acute infections, and the need for rapid etiology-specific therapy, intensive organ support, and early-stage clinical intervention.

 

By Therapy / Treatment Type

Leading Subsegment: Liver Transplantation

Liver transplantation accounts for approximately 38% of the Acute-on-Chronic Liver Failure Market, generating nearly USD 1.273 billion in 2025 revenue. The segment is projected to grow at a CAGR of 6.70% during 2026–2032, reaching about USD 2.00 billion by 2032. Transplantation remains the only definitive life-saving treatment for eligible ACLF patients, with 1-year post-transplant survival exceeding 80%. High short-term mortality, limited curative alternatives, and the need for rapid transplantation within a narrow clinical window sustain market demand for advanced cases.

Fastest-Growing Subsegment: Medications / Pharmacotherapy

Medications and pharmacotherapy accounted for approximately 30% of the Acute-On-Chronic Liver Failure Market, generating nearly USD 1.005 billion in 2025, and are projected to record the fastest treatment CAGR of 9.17% during 2026–2032. Pharmacological management focuses on controlling ACLF triggers and complications through broad-spectrum antimicrobials for infections, norepinephrine or terlipressin with albumin for hepatorenal syndrome, lactulose and rifaximin for hepatic encephalopathy, and selected corticosteroid therapy for severe alcohol-associated hepatitis, while transplantation remains essential for advanced organ failure.

 

By End User

Leading Subsegment: Hospitals

Hospitals dominate the Acute-on-Chronic Liver Failure Market, accounting for approximately 78% of end-user revenue, or USD 2.613 billion in 2025. Hospital-associated revenue is projected to grow at a CAGR of 7.41% during 2026–2032, reaching nearly USD 4.31 billion by 2032. Their leading position reflects the need for ICU monitoring, rapid infection management, hemodynamic stabilization, renal and respiratory support, prognostic assessment, and timely evaluation for emergency liver transplantation among critically ill ACLF patients requiring intensive multidisciplinary care.

Fastest-Growing Subsegment: Specialty Clinics and Research Institutes

Specialty clinics and research institutes account for an estimated 14% of the Acute-on-Chronic Liver Failure Market, representing approximately USD 0.469 billion in 2025 revenue. The segment is projected to expand at the fastest end-user CAGR of 9.40% during 2026–2032, reaching nearly USD 0.88 billion by 2032. Growth is supported by specialized hepatology care, early ACLF monitoring, transplant evaluation, biomarker and multi-omics research, and clinical studies involving plasma exchange, artificial liver support systems, and immune-modulating therapies.

 

By Geography

Leading and Fastest-Growing Region: Asia-Pacific

Asia-Pacific leads the Acute-on-Chronic Liver Failure Market with an estimated 43% share, representing approximately USD 1.441 billion in 2025 revenue, and is projected to reach nearly USD 2.56 billion by 2032. North America also represents an important treatment market, supported by the NACSELD diagnostic framework, which emphasizes severe extrahepatic organ failures in hospitalized cirrhosis patients. Regional treatment demand is influenced by bacterial infections and active alcohol use, which remain prominent precipitating factors for ACLF across Western patient populations.

 

Competitive Landscape: GENFIT Builds the Broadest Clinical-Stage ACLF Pipeline

GENFIT

GENFIT is positioned as a leading clinical-stage company in the Acute-on-Chronic Liver Failure space based on the breadth and advancement of its ACLF-specific pipeline rather than a reported market-share ranking. The company has concentrated its ACLF strategy around two clinical-stage assets—nitazoxanide/G1090N and nangibotide—both moving into Phase 2 development during 2026. This gives GENFIT multiple therapeutic approaches aimed at the systemic inflammation and immune dysregulation that contribute to organ failure in ACLF.

G1090N is a reformulated version of nitazoxanide (NTZ). Phase 1 results announced in January 2026 showed a favorable safety and tolerability profile together with anti-inflammatory activity in ex-vivo assays using samples from study participants and cirrhotic donors. In March 2026, the U.S. FDA granted Orphan Drug Designation to NTZ for ACLF, an important regulatory milestone given that GENFIT states there are currently no specifically approved pharmacological therapies for the condition. A proof-of-concept study was initiated during the third quarter of 2026, with results expected in 2027.

GENFIT further strengthened its ACLF franchise through the 2026 acquisition of nangibotide, a TREM-1 pathway modulator. Nangibotide has already been administered to more than 400 subjects across four clinical studies in acute inflammatory conditions and is being advanced toward a Phase 2a ACLF study, with a data readout targeted for 2027. GENFIT reported EUR 113.8 million in cash and cash equivalents as of June 30, 2026, with its available resources expected to provide a cash runway beyond 2028, supporting continued investment in these programs.

Other Companies Active in the ACLF Treatment Landscape

• Yaqrit: Developing YAQ005, a TLR4 antagonist combined with G-CSF under the G-TAK approach; the first patient was treated in the Phase 2 A-TANGO ACLF trial in July 2026, advancing Yaqrit's targeted anti-inflammatory and liver-regeneration strategy.

• Grifols: Participates in the ACLF treatment landscape through plasma-derived albumin therapies; its development portfolio includes the APACHE program evaluating 5% albumin in acute-on-chronic liver failure, alongside broader albumin research in decompensated cirrhosis and intensive care.

 

Analyst Outlook: Earlier Intervention Broadens the ACLF Treatment Window

The Acute-on-Chronic Liver Failure market is shifting from predominantly supportive critical care toward earlier risk stratification, targeted pharmacotherapy, and more coordinated transplant pathways. The strongest growth opportunities are emerging around therapies that address systemic inflammation and immune dysfunction, improved albumin-based treatment strategies, artificial liver-support systems, biomarker-led patient assessment, and faster referral of eligible patients for transplantation. Clinical programs targeting pathways such as TLR4 and TREM-1 are also expanding the potential pharmaceutical opportunity beyond conventional management.

 

Acute-on-Chronic Liver Failure Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.35 Billion
Revenue Forecast in 2032	USD 5.59 Billion
Overall Growth Rate	CAGR of 7.58% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Therapy / Treatment Type, By End User, By Geography
By Disease Type	Type-A ACLF, Type-B ACLF, Type-C ACLF
By Therapy / Treatment Type	Liver Transplantation, Medications / Pharmacotherapy, Supportive Care, Other Treatments
By End User	Hospitals, Specialty Clinics and Research Institutes, Ambulatory Surgical Centers and Other Outpatient Facilities
By Region	Asia-Pacific, North America, Europe, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Large hospitalized cirrhosis population, high prevalence of extrahepatic organ failure, limited disease-modifying treatment options, increasing demand for pharmacotherapy and organ-support interventions, liver transplantation requirements, and development of targeted therapies addressing systemic inflammation and immune dysfunction
Customization Option	Available upon request